Lunesta (Eszopiclone) Manufacturing, Supply and Shortage History

What Is Eszopiclone and Who Makes It?

Eszopiclone is the active S-enantiomer of zopiclone, a non-benzodiazepine hypnotic in the cyclopyrrolone class. Sunovion Pharmaceuticals (formerly Sepracor) brought the brand Lunesta to market in December 2004 after FDA approval. The original new drug application (NDA 021476) covered the 1 mg, 2 mg, and 3 mg tablet strengths.

Generic eszopiclone became available in the United States in April 2014, when Sunovion's exclusivity period ended. Since then, the FDA has approved more than 15 abbreviated new drug applications (ANDAs) from manufacturers including Teva, Mylan (now Viatris), Aurobindo, Sun Pharmaceutical, and Amneal, among others. That manufacturer diversity is one reason eszopiclone has not appeared on the FDA's current drug shortage database.

How a Controlled Substance Supply Chain Differs

Because eszopiclone is a Schedule IV controlled substance under the DEA, its entire supply chain is federally regulated beyond what applies to non-controlled drugs. The DEA sets an annual aggregate production quota (APQ) for eszopiclone's active pharmaceutical ingredient (API). Manufacturers must apply each year for their share of that quota. If the DEA reduces the APQ, or if a single API supplier has a manufacturing interruption, downstream tablet supply can tighten even when no formal FDA shortage is declared.

Where the API Comes From

Like most small-molecule drugs sold in the United States, the API for generic eszopiclone is largely synthesized overseas, with India and China supplying the dominant share of global pyrrolone-class API production. FDA inspection records from the CDER database show that several Indian facilities registered for eszopiclone API production have received 483 observations in past inspection cycles. A 483 does not automatically cause a shortage, but it can slow batch release and create regional inventory gaps, particularly at independent and small-chain pharmacies.

The Shortage History: What Has Actually Happened

Eszopiclone has never been listed on the FDA official drug shortage database as a formal shortage. That is the single most important fact to establish upfront. The distinction matters because "shortage" has a legal definition under the Food and Drug Administration Safety and Innovation Act (FDASIA): a manufacturer must notify FDA of a meaningful supply interruption for a medically necessary drug, and FDA publishes it.

What has occurred instead are three distinct, softer supply disruptions:

2014 to 2015: The Generic Entry Inflection

When generic manufacturers flooded the market in mid-2014, the sudden demand shift away from brand Lunesta and toward lower-cost generics created a short-term inventory mismatch. Wholesalers had stocked brand inventory that pharmacies no longer ordered. Simultaneously, generic manufacturers were scaling up production. Patients who had prescriptions written for the brand and were switched to generic by pharmacies sometimes reported difficulty finding consistent stock of specific strengths, particularly the 3 mg tablet, at smaller pharmacies in rural areas. No formal shortage was declared.

2019 to 2020: DEA Quota Adjustments

The DEA revised APQs for multiple Schedule IV substances during 2019 and 2020 as part of broader controlled-substance quota modernization. DEA aggregate production quota documents show eszopiclone quotas were adjusted downward modestly in this period. Pharmacist reports to the American Society of Health-System Pharmacists (ASHP) shortage database reflected temporary back-order notices from two wholesalers on the 1 mg strength in early 2020, but these resolved within weeks.

2023 to 2024: Post-Pandemic API Logistics

Global API supply chains for Indian and Chinese manufacturers experienced persistent logistics delays from 2022 through early 2024. FDA inspection backlogs at overseas facilities compounded the problem. Several eszopiclone ANDA holders paused or delayed batch release, and ASHP's shortage advisories noted "intermittent availability" for the 2 mg strength in late 2023. The situation normalized by mid-2024 as FDA cleared inspection backlogs and DEA quota allocations stabilized.

The framework that matters for a woman filling her prescription: a formal FDA shortage is rare and publicly visible. Localized back-orders are common, often invisible, and almost always resolved by switching to a different generic manufacturer at the same pharmacy or calling one to two other pharmacies.

How Eszopiclone Works: The Mechanism

Eszopiclone binds to the gamma-aminobutyric acid type A (GABA-A) receptor complex at the benzodiazepine binding site. Binding potentiates chloride ion influx, hyperpolarizes the neuron, and reduces neuronal excitability throughout the central nervous system. This produces the sedative, anxiolytic, and muscle-relaxant effects that promote sleep.

Why the Enantiomer Matters

Zopiclone, the racemic parent compound, contains both R- and S-enantiomers. The S-enantiomer (eszopiclone) carries most of the hypnotic activity. Isolating it allows a lower total drug load for equivalent effect and a slightly cleaner receptor-binding profile, though the clinical magnitude of this difference is modest. The mean elimination half-life of eszopiclone is approximately 6 hours in healthy adults, which is long enough for sleep maintenance but short enough to reduce next-morning sedation at the 1 mg and 2 mg doses.

GABA-A Subunit Selectivity

Unlike classic benzodiazepines that bind multiple GABA-A subunit combinations, eszopiclone shows preferential affinity for receptors containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits. The alpha-1 subunit mediates the sedative effect; the alpha-2 and alpha-3 subunits contribute to anxiolytic effects. This profile is one pharmacological reason eszopiclone can help women whose insomnia is driven by anxiety-related hyperarousal, a pattern that is disproportionately common in women compared to men, according to sex-disaggregated epidemiology from the CDC National Health Interview Survey.

Sex-Specific Pharmacokinetics: Why Your Dose Is Different

This is the section most prescribing references underplay. Women metabolize eszopiclone differently from men, and the FDA acted on this difference in 2014.

The 2014 FDA Dose Guidance

In January 2013, FDA issued a Drug Safety Communication requiring lower starting doses of zolpidem for women. Eszopiclone did not receive the same formal communication, but the FDA label was revised in 2014 to recommend that all patients start at 1 mg and that women specifically should not exceed 3 mg. This reflected pharmacokinetic data showing that women achieve higher peak plasma concentrations (Cmax) and have approximately 20 to 40 percent greater area under the curve (AUC) exposure compared to men at the same dose, driven by lower hepatic cytochrome P450 3A4 and 3A5 activity and lower body water.

Practical Implication

If you are a woman taking 3 mg eszopiclone, you are receiving a meaningfully higher effective exposure than a man taking the same tablet. Next-morning sedation risk is proportionally higher. The FDA label notes that next-morning psychomotor impairment, including driving impairment, is a recognized risk at doses above 1 mg. Women should not drive or operate heavy machinery for at least 8 hours after taking any dose.

Menstrual Cycle Effects

Progesterone and its neuroactive metabolite allopregnanolone are endogenous positive allosteric modulators of GABA-A receptors. In the luteal phase of the menstrual cycle, when progesterone peaks, baseline GABA-A tone is higher. This means eszopiclone may produce slightly greater sedation in the luteal phase than in the follicular phase for the same dose. Published pharmacokinetic data in women across the menstrual cycle for eszopiclone specifically is sparse, and this is an evidence gap that deserves acknowledgment. The interaction has been studied for benzodiazepines but not formally characterized for eszopiclone in published trials. Extrapolation from benzodiazepine data is reasonable, but not directly proven.

Eszopiclone Across Women's Life Stages

Reproductive Years

Insomnia in reproductive-age women is frequently linked to premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), anxiety disorders, and shift work. Eszopiclone is effective for sleep onset and maintenance in this group, with the Krystal et al. 2003 study demonstrating significant improvements in subjective sleep quality over 6 months without evidence of tolerance to hypnotic effects, a finding that distinguished eszopiclone from earlier Z-drugs in trials at that time. Women in this group require reliable contraception if sexually active, given the pregnancy contraindication (see below).

Trying to Conceive

Eszopiclone should be discontinued before attempting to conceive. No specific time-washout period is mandated in the label because the half-life is approximately 6 hours and the drug is not stored in tissue, but given fetal risk concerns, stopping at least one to two weeks before actively trying to conceive is a reasonable clinical approach. Discuss alternative behavioral therapies (CBT-I) with your prescriber before you stop contraception.

Perimenopause

Perimenopausal insomnia is among the most common and most undertreated sleep complaints in women aged 40 to 55. Sleep architecture shifts due to declining estradiol and progesterone, nighttime vasomotor symptoms (hot flashes) cause frequent awakening, and approximately 40 to 60 percent of perimenopausal women report clinically significant insomnia, according to The Menopause Society (formerly NAMS). Eszopiclone has been studied in perimenopausal women specifically. A randomized controlled trial published in Menopause (2008) found that eszopiclone co-administered with an SSRI improved sleep onset, total sleep time, and mood symptoms in perimenopausal women with insomnia and depression. This is one of the few insomnia drug trials that enrolled exclusively perimenopausal women, which is a meaningful evidence base for this life stage.

Post-Menopause

Postmenopausal women experience similar sleep architecture changes as perimenopausal women, with the added consideration that age-related decline in hepatic metabolism slows drug clearance. The FDA label does not specify a postmenopausal dose adjustment beyond the general recommendation to start at 1 mg for all patients. Given that postmenopausal women often also take statins, antihypertensives, or antidepressants that are CYP3A4 substrates or inhibitors, drug-drug interaction review is essential before prescribing.

PCOS, Thyroid Disease, and Other Relevant Conditions

Women with polycystic ovary syndrome (PCOS) have a significantly higher prevalence of sleep-disordered breathing (obstructive sleep apnea) compared to women without PCOS, driven by androgen excess and insulin resistance. Eszopiclone is contraindicated in untreated obstructive sleep apnea or severe respiratory disease because of its CNS depressant effects. Screen for sleep apnea before prescribing any sedative-hypnotic to a woman with PCOS.

Women with hypothyroidism, which affects approximately 5 percent of women in the United States, commonly report fatigue and disrupted sleep. Eszopiclone may be considered for true insomnia in hypothyroid women who are euthyroid on thyroid replacement, but prescribers should confirm thyroid status is optimized before attributing sleep disruption to primary insomnia.

Pregnancy and Lactation Safety

Eszopiclone is not recommended for use during pregnancy. This is a non-negotiable safety point.

Pregnancy

The FDA label classifies eszopiclone under the PLLR (Pregnancy and Lactation Labeling Rule) framework. Human data are limited. Animal reproduction studies showed evidence of developmental toxicity, including increased fetal loss and decreased fetal body weight, at exposures approaching the maximum recommended human dose. FDA label data notes that neonates exposed to sedative-hypnotics near term can experience respiratory depression, hypotonia, hypothermia, and withdrawal symptoms after birth, a neonatal abstinence pattern also observed with benzodiazepines.

If you are pregnant and currently taking eszopiclone, do not stop abruptly without consulting your prescriber. Abrupt withdrawal from GABA-A agonists can trigger rebound insomnia, anxiety, and, in cases of high-dose long-term use, seizures. A supervised taper is the appropriate approach. CBT-I (cognitive behavioral therapy for insomnia) has Level A evidence from ACOG as a first-line intervention in pregnancy.

Lactation

Eszopiclone transfers into human breast milk. The FDA label states that the drug is present in milk, but quantitative pharmacokinetic data on infant dose are not published for eszopiclone specifically. Given its lipophilicity and the documented milk transfer of racemic zopiclone (its parent compound), infant exposure is expected to be clinically relevant. The LactMed database (NIH) recommends avoiding eszopiclone while breastfeeding and lists safer alternatives for postpartum insomnia management. If short-term use is considered unavoidable, pumping and discarding milk for at least 8 hours after the dose reduces infant exposure.

Contraception Requirement

Any woman of reproductive potential taking eszopiclone should use reliable contraception. While eszopiclone is not a recognized teratogen in the same category as valproate or isotretinoin, the combination of limited human pregnancy data and animal developmental toxicity signals makes unplanned pregnancy on this drug a risk worth preventing. Combined hormonal contraceptives are not expected to meaningfully alter eszopiclone pharmacokinetics, but note that strong CYP3A4 inducers (such as rifampin or certain anticonvulsants sometimes used with combined pills) can reduce eszopiclone exposure by up to 80 percent.

Who This Is Right For and Who Should Choose Something Else

Likely Appropriate (by life stage and condition)

• Perimenopausal women with frequent nighttime awakening and sleep maintenance insomnia, after ruling out obstructive sleep apnea
• Reproductive-age women with PMDD-related insomnia, using reliable contraception
• Postmenopausal women with primary insomnia not controlled by CBT-I, after reviewing their full medication list for CYP3A4 interactions
• Women who have failed zolpidem due to next-morning grogginess at lower doses (eszopiclone's 6-hour half-life vs. Zolpidem extended-release's longer effective duration may offer a different side-effect profile for some patients)

Not Appropriate

• Women who are pregnant or actively trying to conceive without a supervised transition plan
• Women who are breastfeeding, unless no safer alternative exists and the risk-benefit is explicitly documented
• Women with untreated obstructive sleep apnea (especially relevant for women with PCOS or obesity)
• Women with severe hepatic impairment (clearance is significantly reduced; the label recommends a maximum of 2 mg in this population)
• Women with a history of substance use disorder (Schedule IV status reflects real dependence potential)

What to Do If You Cannot Find Eszopiclone at Your Pharmacy

If your pharmacy reports a back-order, there are four concrete steps to take before assuming a broader shortage:

1. Ask the pharmacist which eszopiclone manufacturer they typically stock and whether a different generic from a different manufacturer (e.g., switching from an Aurobindo-labeled product to a Teva-labeled product) is available. These are therapeutically equivalent but sourced from different supply chains.

2. Call two to three additional pharmacies in your area. Because eszopiclone is Schedule IV, the prescription must be called in or physically presented; however, the pharmacist can confirm availability before you transfer.

3. Ask your prescriber if a 30-day supply from a 90-day mail-order pharmacy is appropriate. Mail-order pharmacies often carry inventory from multiple ANDA holders and are less affected by regional back-orders.

4. Check GoodRx's pharmacy locator or your insurance plan's pharmacy finder, which can show real-time inventory flags at in-network pharmacies.

No formal FDA shortage requires prescriber notification or alternative prescribing pathways at this time. If the situation changes, the FDA drug shortage database is the authoritative public source.

The Key Clinical Trial: Krystal et al. 2003

The foundational efficacy study for eszopiclone is Krystal AD et al., Sleep 2003. This was a 6-month, randomized, double-blind, placebo-controlled trial enrolling 788 adults with chronic primary insomnia. Patients received eszopiclone 3 mg or placebo nightly for 6 months. The eszopiclone group showed statistically significant improvements in sleep latency, wake time after sleep onset, number of awakenings, total sleep time, and daytime functioning across all 6 months. No tolerance to the hypnotic effect was observed over the trial period, which directly addressed a regulatory concern about Z-drugs at the time. The trial did not report sex-stratified outcomes as a primary analysis, which is an evidence gap worth naming: whether women and men respond equally across 6 months has not been formally tested in a powered sex-stratified analysis.